An observational study in Hepatocellular Carcinoma and Cirrhosis, sponsored by Xiao Xu. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2024-05-20.
Sponsored by Xiao Xu · Observational
Background: This study aims to investigate the correlation between cirrhosis and hepatocellular carcinoma (HCC) recurrence after Liver Transplantation.
Methods: The study retrospectively collected data enrolled from 519 HCC patients who underwent liver transplantation from two center(the First Affiliated Hospital, Zhejiang University School of Medicine and Shulan (Hangzhou) Hospital, January 2015 to December 2020), Based on important variables, 1:3 propensity score matching (PSM) were performed respectively.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 1 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Xiao Xu is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Previously registered liver transplant recipients
The patients undergoing liver transplantation for HCC from January 2015 to December 2020.
Exclusion Criteria:
Re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 90 days.
The overall survival rate was evaluated by follow-up investigation and outpatient review
Time frame: 2-5 years
The tumor-free survival rate was evaluated by follow-up investigation and outpatient review
Time frame: 2-5 years
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiao Xu